Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,866 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Katayama Y, et al. Among authors: nakamura r. NPJ Precis Oncol. 2023 Jan 26;7(1):12. doi: 10.1038/s41698-023-00350-7. NPJ Precis Oncol. 2023. PMID: 36702855 Free PMC article.
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.
Morimoto K, Yamada T, Nakamura R, Katayama Y, Tanaka S, Takumi C, Hiraoka N, Ogura Y, Takeda T, Onoi K, Chihara Y, Taniguchi R, Yamada T, Matsui Y, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: nakamura r. Med Oncol. 2020 Nov 11;37(12):111. doi: 10.1007/s12032-020-01440-3. Med Oncol. 2020. PMID: 33175248
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
Nakamura R, Yamada T, Morimoto K, Nakao A, Goto Y, Ogura Y, Takeda T, Takumi C, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Tanaka S, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Uchino J, Takayama K. Nakamura R, et al. J Cancer Res Clin Oncol. 2022 Nov;148(11):2985-2994. doi: 10.1007/s00432-021-03866-2. Epub 2021 Nov 26. J Cancer Res Clin Oncol. 2022. PMID: 34825950
Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
Tanaka S, Uchino J, Yokoi T, Kijima T, Goto Y, Suga Y, Katayama Y, Nakamura R, Morimoto K, Nakao A, Hibino M, Tani N, Takeda T, Yamaguchi H, Tachibana Y, Takumi C, Hiraoka N, Takeshita M, Onoi K, Chihara Y, Taniguchi R, Yamada T, Matsui Y, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Yamada T, Takayama K. Tanaka S, et al. Among authors: nakamura r. Diagnostics (Basel). 2022 Feb 6;12(2):423. doi: 10.3390/diagnostics12020423. Diagnostics (Basel). 2022. PMID: 35204513 Free PMC article.
Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non-small cell lung cancer.
Nakamura R, Yamada T, Tanaka S, Sasada A, Shiotsu S, Tani N, Takeda T, Chihara Y, Hirai S, Takemura Y, Yoshimura A, Morimoto K, Iwasaku M, Tokuda S, Kim YH, Takayama K. Nakamura R, et al. Cancer Med. 2023 Apr;12(8):9097-9105. doi: 10.1002/cam4.5647. Epub 2023 Jan 27. Cancer Med. 2023. PMID: 36707978 Free PMC article.
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.
Hirai S, Yamada T, Katayama Y, Ishida M, Kawachi H, Matsui Y, Nakamura R, Morimoto K, Horinaka M, Sakai T, Sekido Y, Tokuda S, Takayama K. Hirai S, et al. Among authors: nakamura r. Mol Cancer Ther. 2024 Feb 1;23(2):212-222. doi: 10.1158/1535-7163.MCT-23-0138. Mol Cancer Ther. 2024. PMID: 37802502 Free PMC article.
Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.
Yamada Y, Tamura T, Yamamoto Y, Ichimura H, Hayashihara K, Saito T, Yamada H, Endo T, Nakamura R, Inage Y, Satoh H, Iguchi K, Saito K, Inagaki M, Kikuchi N, Kurishima K, Ishikawa H, Sakai M, Kamiyama K, Shiozawa T, Hizawa N, Sekine I, Sato Y, Funayama Y, Miyazaki K, Kodama T, Hayashi S, Nomura A, Nakamura H, Furukawa K, Yamashita T, Okubo H, Suzuki H, Kiyoshima M, Kaburagi T. Yamada Y, et al. Among authors: nakamura h, nakamura r. Anticancer Res. 2020 Oct;40(10):5757-5764. doi: 10.21873/anticanres.14592. Anticancer Res. 2020. PMID: 32988903 Clinical Trial.
A population-based study of outcomes in patients with surgically resected non-small cell lung cancer with anaplastic lymphoma kinase-rearranged mutations: A matched-pair study.
Inagaki M, Ichimura H, Usui S, Iguchi K, Ishibashi O, Nakamura R, Inage Y, Suzuki H, Kiyoshima M, Kamiyama K, Kimura M, Yoshida S, Sakai M, Kobayashi N, Furukawa K, Satoh H, Hizawa N, Sato Y. Inagaki M, et al. Among authors: nakamura r. Mol Clin Oncol. 2021 Jan;14(1):11. doi: 10.3892/mco.2020.2173. Epub 2020 Nov 19. Mol Clin Oncol. 2021. PMID: 33282286 Free PMC article.
Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI).
Tamura T, Numata T, Yanai H, Nakamura R, Shiozawa T, Watanabe H, Okauchi S, Kikuchi N, Miyazaki K, Hayashi S, Yamashita T, Kurishima K, Inagaki M, Satoh H, Ishikawa H, Kaburagi T, Endo T, Sakamoto T, Hizawa N. Tamura T, et al. Among authors: nakamura r. Anticancer Res. 2023 Oct;43(10):4583-4591. doi: 10.21873/anticanres.16652. Anticancer Res. 2023. PMID: 37772562
2,866 results